Skip to Main Content

Paper Details

Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Eur J Cancer
12
2021
BDII, BET, BMS-986158, CC-90010, MYC, MYCN, NUT, NUT carcinoma, bromodomain and extra-, bromodomain fusions, cancer, child, children, fusion-driven malignancies, malignancy, nuclear protein in testis) carcinomas, p300, paediatric, paediatric malignancies, patient, patients, thrombocytopenia, tumour
Author NameAffiliation
Steven G DuBoisDana-Farber Cancer Institute/Harvard Medical School
Mark W Kieran
Mark W Kieran
Kimberly StegmaierDana-Farber Cancer Institute/Harvard Medical School
Kimberly StegmaierDana-Farber Cancer Institute/Harvard Medical School
Pratiti BandopadhayayDana-Farber Cancer Institute/Harvard Medical School
Franck BourdeautInstitut Curie
Patrick BrownJohns Hopkins Kimmel Cancer Center
Patrick BrownJohns Hopkins Kimmel Cancer Center
Elizabeth FoxSt Jude Children's Research Hospital
John M MarisChildren's Hospital of Philadelphia
John M MarisChildren's Hospital of Philadelphia
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Rajeev VibhakarUniversity of Colorado and Children's Hospital Colorado
Gilles Vassal
  • 1 - 16

Datasets

Release 1.2